SETD7, His, Human
SETD7, His, Human

The purity of SETD7, His, Human is greater than 95% as determined by SEC-HPLC.

SETD7, His, Human

SETD7, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SETD7, His, Human

SETD7 is a methyltransferase that specifically catalyzes the monomethylation of lysine 4 on histone H3. A variety of studies has revealed the role of SETD7 in posttranslational modifications of non-histone proteins. Aberrant expression of SETD7 has been associated with various diseases, including cancer. As a prognostic marker of breast cancer and a novel antioxidant promoter under oxidative stress in breast cancer, SETD7 is considered a good target for the development of new epigenetic drugs.
Z05808
¥69,021.00

Ask us a question
Product Introduction
Species Human
Protein Construction
His SETD7 (Met1-Lys366)_x000D_
Accession # NP_085151.1
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System E.coli
Theoretical Molecular Weight 41.68 kDa
Apparent Molecular Weight The protein migrates to 47-50 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • SETD7, His, Human
    • SETD7, His, Human

    The purity of SETD7, His, Human is greater than 95% as determined by SEC-HPLC.

  • SETD7, His, Human
    • SETD7, His, Human

    SETD7, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background SETD7 is a methyltransferase that specifically catalyzes the monomethylation of lysine 4 on histone H3. A variety of studies has revealed the role of SETD7 in posttranslational modifications of non-histone proteins. Aberrant expression of SETD7 has been associated with various diseases, including cancer. As a prognostic marker of breast cancer and a novel antioxidant promoter under oxidative stress in breast cancer, SETD7 is considered a good target for the development of new epigenetic drugs.
Synonyms KIAA1717; KMT7; SET7; SET9; SET7/9

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.